Does the Diagnosis of Intraoperative Malignant Hyperthermia Require Case Termination? A Case Report

Alessandra M Riccio1, Dana L Gurvitch

  • 1From the Department of Anesthesiology, New York Presbyterian Hospital, Weill Cornell Medical Center, New York, NY.

A&A Practice
|January 10, 2025
PubMed

Insights

Malignant hyperthermia (MH), a rare genetic disorder, can occur during anesthesia. This case highlights successful intraoperative management of MH, enabling surgery continuation and preventing nerve damage.

Area of Science:

  • Anesthesiology
  • Pharmacology
  • Genetics

Background:

  • Malignant hyperthermia (MH) is a rare, life-threatening pharmacogenetic disorder.
  • Triggered by volatile anesthetics and succinylcholine, MH involves hypermetabolism and muscle rigidity.
  • Prompt diagnosis and treatment are crucial to prevent mortality.

Observation:

  • A healthy 39-year-old male developed MH hours into an anesthetic procedure.
  • The patient experienced symptoms indicative of malignant hyperthermia during surgery.
  • The surgical case was at risk of termination due to the patient's condition.

Findings:

  • Rapid intraoperative stabilization strategies were implemented, mirroring intensive care unit (ICU) protocols.
  • These interventions allowed for the continuation of the planned surgical procedure.
  • The patient's condition was managed effectively without aborting the surgery.

Implications:

  • Demonstrates the feasibility of continuing complex surgeries in MH patients with aggressive management.
  • Highlights the importance of preparedness and advanced critical care capabilities in the operating room.
  • Suggests that timely and intensive interventions can mitigate risks associated with MH during anesthesia.